



Understanding Tuberculosis: Causes, Treatment, and Prevention

Aadil bashir¹, Mr. Pankaj Chastasi², Ms. Tanya Sharma³

¹ Student of pharmaceutical science at Mewar University

² Assistant professor faculty of pharmaceutical science At Mewar University

³ HOD of pharmaceutical Science at Mewar University.

ABSTRACT:

Tuberculosis (TB), one of the oldest ailments affecting humans, is a primary cause of global mortality and is caused by bacteria from the *Mycobacterium tuberculosis* complex. The WHO states that tuberculosis ranks as the second highest cause of death globally, following HIV/AIDS, and it continues to pose a significant risk to human health. Tuberculosis is highly prevalent among individuals from lower socioeconomic backgrounds and marginalized groups within the community.

The primary goal of India's National Strategic Plan (2017–2025) is to eliminate tuberculosis by the year 2025. It requires an enhanced understanding and awareness of tuberculosis. This review article encompasses the history, pathophysiology, immunology, histology, epidemiology, taxonomy, and clinical features of extra-pulmonary tuberculosis (EPTB) and pulmonary tuberculosis (PTB). The diagnostic approach for PTB and EPTB, along with extensive details regarding diagnostic methods, has been outlined. A recap of treatment strategies for extensive, drug-resistant, and sensitive tuberculosis has been included, alongside the most recent medications recommended for multidrug-resistant tuberculosis. In a genuine effort to eliminate tuberculosis from the earth soon, this review article was developed after an extensive literature review aimed at enhancing understanding and increasing awareness of the disease.

Keywords: Tuberculosis, *Mycobacterium tuberculosis*, Pulmonary Tuberculosis (PTB), Extra-pulmonary Tuberculosis (EPTB), Epidemiology, Pathophysiology, Immunology

INTRODUCTORY SECTION

“A dreadful condition where the battle between the body and the soul is gradual, quiet, and grave, leading to an inevitable outcome in which the physical form diminishes and deteriorates slowly, piece by piece.” An illness that may advance at a slow pace or a rapid one, yet it is always inevitable and definitive regardless of its speed. Nicholas Nickleby, authored by Charles Dickens.

The remarks of Charles Dickens remain true even now. Referred to as consumption in Dickens' time, tuberculosis has troubled humanity for centuries and has exerted a considerable social and economic influence on the lives of individuals globally. One Humankind has observed the transformation of tuberculosis (TB) from an unmanageable disease to one that can be treated. After the emergence of the HIV/AIDS epidemic in 1981, TB experienced a global resurgence due to the deadly and unfortunate co-infection of HIV and TB. Please provide the text you would like me to paraphrase. A variant of tuberculosis resistant to drugs led to the deaths of 80% of those infected during an outbreak in New York in the early 1990s. Certainly! Please provide the text you'd like me to paraphrase.

The circumstances Have deteriorated significantly because of the co-infection of HIV and TB, along with the rise of drug-resistant TB, prompting the WHO to classify TB as a global emergency in 1993. Sure! Please provide the text you would like me to paraphrase. According to clinical signs, tuberculosis is categorized as either pulmonary TB (PTB) or extrapulmonary TB (EPTB), even though its manifestations differ. It seems like there is no text provided for me to paraphrase. Please share the text you'd like me to paraphrase, and I'll be happy to help! When tuberculosis impacts organs beyond the lungs, including the pleura, lymph nodes, abdomen, genitourinary system, skin, joints, bones, or meninges, it is known as EPTB. A patient diagnosed with EPTB is considered to have pulmonary TB (like military TB) if they also possess a tuberculous lesion in the lung tissue.

EPTB is characterized by TB pleural effusion without any radiological abnormalities evident in the lungs or intra-thoracic mediastinal and/or hilar lymph nodes affected by TB. Sure! Please provide the text you would like me to paraphrase. As per WHO estimates, there were 10.4 million tuberculosis cases globally in 2017, with 77% of these cases reported in India, 9% in China, 8% in Indonesia, 6% in the Philippines, 5% in Pakistan, 4% in Nigeria, 4% in Bangladesh, and 3% in South Africa. Between 15 and 20 percent of all tuberculosis cases are extrapulmonary tuberculosis (EPTB). As over 50% of TB diagnoses in people with HIV are EPTB, the ongoing HIV pandemic complicates the situation further. 7 EPTB may present in numerous ways, making prompt diagnosis very difficult. It might manifest as constitutional signs such as fatigue, fever, loss of appetite, weight reduction, and general unease. 8 In India, fever of unknown origin might be the sole indication due to the infection's isolated location. Nine

HISTORICAL BACKGROUND

Historically, numerous civilizations have documented instances of tuberculosis or similar illnesses dating back to ancient times. The Vedas contain the oldest recorded reference to TB, referred to as Yakshma, implying a wasting disease. A TB-like disease is also mentioned in Greek, Chinese, and Arabic texts. 2 Mycobacteria have existed on Earth for the last 150 million years. Mummies from the pre-dynastic Egyptian and pre-Columbian Peruvian eras both exhibit characteristic tubercular spinal lesions. The early uncertain evidence of tuberculosis.

The genus Mycobacterium TB is categorized within the ORDER-Actinomycetales and CLASS-Actinomycetes. GENUS: Mycobacterium; FAMILY: Mycobacteriaceae. The genera Gordonia, Tsukamurella, Nocardia, and Rhodococcus are closely associated with Mycobacterium.

EPIDEMIOLOGY

The research on epidemiology indicates that almost one-third of the global population is infected with *M. tuberculosis* bacilli, presenting a lifetime risk of 10% for developing TB disease. Sure! Please provide the text you'd like me to paraphrase. In 2017, there were 10.4 million tuberculosis cases globally, equating to 133 cases for every one million individuals. Among these, 90% were adults (defined as those older than 15), 64% were male, and 9% were people living with HIV, with 72% of these cases reported in Africa [Fig. 1]. Rifampicin-resistant TB (RR-TB) was projected to have arisen in 558,000 new instances (range: 483,000–639,000), with more than half of these cases found in three countries:

The development of disease

The pathogenesis A small fraction of droplet nuclei containing MTB from infected individuals reach the alveoli; most are trapped in the upper airway and expelled by ciliated mucosal cells. The mycobacteria then adhere to the cell surface of alveolar macrophages through type A scavenger receptors, complement receptors, or mannose receptors. Mycobacteria lower the acidity of phagosomes post-phagocytosis, and a cell wall element named lipoarabinomannan interferes with the Ca⁺/calmodulin pathway, hindering the phagosome-lysosome fusion.

TISSUE STUDY

The examination of histology reveals pathognomonic lesions known as tubercles at every infection location associated with PTB or EPTB. This represents a typical granulomatous inflammatory reaction by the host's cell-mediated defense against MTB bacilli. Initially tiny, these tubercles ultimately merge to create granulomas that are noticeable at the macroscale. The granulomas consist of lymphocytes, giant multinucleated cells surrounded by a fibroblastic ring, fibrin-rich exudate in the alveoli, and MTB bacilli found in macrophages.

CLINICAL CHARACTERISTICS:

Clinical features Due to EPTB being rarer than PTB, physicians encounter it less often, and it may be difficult to identify clinically.

MILITARY TUB

TB in the military presents clinical symptoms that are usually nonspecific and may involve weakness, lack of appetite, fever, weight loss, and night sweats. Fever, weight loss, hepatomegaly, respiratory findings, lymph node enlargement, and splenomegaly are the physical signs presented in descending order. A retinal choroid granuloma strongly indicates the presence of extensive tuberculosis.

Lymphadenitis due to tuberculosis

(TBL) is a tuberculosis infection that impacts the lymph nodes, resulting in lymphadenopathy. It is the most prevalent type of extrapulmonary tuberculosis, typically caused by *Mycobacterium tuberculosis*. TBL may engage bilateral, non-adjacent lymph nodes, but typically targets one group of nodes, usually found in the neck. When cervical lymph nodes are impacted, It is referred to as "scrofula" and results in visible swelling.

INDICATORS

Signs of TB Symptoms of active tuberculosis consist of:

A persistent cough that continues for over two weeks

Discomfort in the chest

Coughing up sputum (mucus) or blood

Lack of strength or energy

Loss of appetite

Weight loss

High temperature

Nighttime perspiration

What is the mode of transmission for tuberculosis?

When a person with active tuberculosis coughs, sneezes, talks, sings, or laughs, it can transmit. Individuals are contagious solely when they are suffering from an active lung infection. TB is usually acquired through extended exposure to an infected individual. Most individuals who breathe in TB bacteria manage to fight off the infection and stop its development. This leads to a latent TB infection.

FACTORS OF RISK

Risk factors You may be at a higher risk of TB exposure if you: live or work in an environment where tuberculosis can be transmitted, like a prison, hospice, skilled nursing home, shelter, or another healthcare setting?

Employed in a laboratory focused on mycobacteriology. Lived in regions with high tuberculosis rates, including Latin America, the Caribbean, Africa, Asia, Eastern Europe, and Russia. Engaged with someone who was suspected or confirmed to have tuberculosis.

Your likelihood of developing active tuberculosis may rise if you: administer intravenous medication injections, have an immune system that is underdeveloped, weakened, or inadequate (such as infants and children), or have diabetes, kidney disease, or another chronic condition.

Evaluation and Identification

How doctors recognize tuberculosis To find tuberculosis,

Healthcare providers use a blood or skin test.

You might also need: Laboratory tests for sputum and lung fluid.

CT (computed tomography)

Images of the chest

Laboratory testing:

To achieve a conclusive diagnosis of tuberculosis, it is essential to show *M. tuberculosis* bacilli through microbiological, cytopathological, or histological methods. Two phenotypic characterizations of colonies cultivated on Lowenstein-Jensen medium represent a conventional laboratory technique for identifying mycobacterial infections. To swiftly detect mycobacteria, it is presently recommended to use a combination of phenotypic and molecular tests.

The approach to care

Treatment for drug-sensitive TB in people living with HIV, pediatric TB cases across the country, and all TB cases in 104 districts, the RNTCP (currently referred to as the National Tuberculosis Elimination Program) has established a daily treatment schedule. All newly diagnosed TB cases with drug-sensitive strains enter an 8-week intensive phase (IP) that includes isoniazid (H), rifampicin ®, pyrazinamide (Z), and ethambutol € administered daily based on four weight category classifications. The other three drugs, excluding pyrazinamide, persist in the continuation phase (CP) for another 16 weeks.

SUMMARY

In summary, over a hundred years have elapsed since the identification of tubercle bacilli, and Robert Koch's assertion that "even with the ongoing diverse methods to combat tuberculosis, we must still inquire what measures most effectively meet scientific standards" remains pertinent today. Sure! Please provide the text you'd like me to paraphrase. TB continues to present a challenge for doctors, pathologists, and microbiologists in every aspect, and the issue of early identification and treatment of all types of the disease remains a concern today. WHO ELIMINATES TB

REFERENCES

- 1 Global Health Organization. (2020). *Worldwide Tuberculosis Report 2020*. WHO Media.
- 2 Dheda, K., Barry, C. E., & Maartens, G. (2016). Tuberculosis. *The Lancet*, 387(10024), 1211-1226.
- 3 Lawn, S. D., & Zumla, A. I. (2011). Tuberculosis. *The Lancet*, 378(9785), 57-72.
- 4 Gagneux, S. (2018). Ecological and evolutionary aspects of *Mycobacterium tuberculosis*. *Nature Reviews Microbiology*, 16(4), 202-213.
- 5 . Pai, M., Schito, M., & Dheda, K. (2016). Progress in tuberculosis testing methods. *Nature Reviews Disease Primers*, volume 2, article 16076.
6. Zumla, A., Raviglione, M., & Hafner, R. (2013). Tuberculosis. *The New England Journal of Medicine*, 368(8), 745-755.
- 7 Cohen, K. A., Manson, A. L., and Abeel, T. (2019). Development of highly drug-resistant tuberculosis over a period of forty years. *Nature Communications*, 10(1), 1-11.
- 8 Tiberi, S., du Plessis, N., & Walzl, G. (2018). Tuberculosis: Advances and progress in the creation of new medications, treatment protocols, and host-targeted therapies. *The Le, and I'll be happy to help!* Sharma, S. K., & Mohan, A. (2017). Tuberculosis outside the lungs. *Indian Journal of Medical Research*, 145(4), 448-463.
- 9 Migliori, G. B., Thongpdee, N., e Alffenaar, J. W. (2020). Personalized treatment for tuberculosis: A research-supported manual. *Clinical Microbiology and Infection*, 26(10), 1230-1241.
10. Floyd, K., Glaziou, P., & Houben, R. (2018). Worldwide tuberculosis epidemiology. *The Lancet Infectious Diseases*, 18(3), 258-272.
- 11 Allué-Guardia, A., García, J. I., y Torrelles, J. B. (2021). Development of *Mycobacterium tuberculosis* virulence. *Pathogens*, 10(2), 134.
- 12 Lönnroth, K., Jaramillo, E., & Williams, B. G. (2009). Factors contributing to tuberculosis epidemics: The Influence of risk elements and social determinants. *The Lancet*, 373(9667), 537-552.
- 13 Menzies, D., Al Jhdali, H., & Al Otaibi, B. (2011). Recent advancements in the management of latent tuberculosis infection. *Chest*, 139(3), 715-732.
- 14 Udawadia, Z. F., Amale, R. A., & Ajbani, K. (2012). Completely drug-resistant tuberculosis in India. *Clinical Infectious Diseases*, 54(4), 579-581.
- 15 World Health Organization. (2019). *WHO Unified Guidelines on Tuberculosis: Preventive Treatment for Tuberculosis*. WHO Newsroom.
- 16 Yuen, C. M., Amanullah, F., & Dharmadhikari, A. (2015). Shutting off the faucet: Halting tuberculosis
- 17 Spread by actively identifying cases and providing timely, effective treatment. *The Lancet*, 386(10010), 2334-2343.
18. Raviglione, M., & Sulis, G. (2016). Tuberculosis 2016: Manage or eradicate? *Frontiers in Medicine*, Volume 3, Page 10.
19. Gandhi, N. R., Nunn, P., & Dheda, K. (2010). Multidrug-resistant and extensively drug-resistant tuberculosis: A danger to worldwide tuberculosis management. *The Lancet*, 375(9728), 1830-1843.
- 20 Daley, C. L., and Caminero, J. A. (2019). Administration of multidrug-resistant tuberculosis. *Clinical Chest Medicine*, 40(4), 775-795.